Review paper
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
Abstract
HER2-positive (HER2+) breast cancer represents a heterogeneous breast cancer subtype, including both oestrogen receptor (ER) positive and negative tumours. A deeper understanding of the crosstalk between ER and HER2 receptor pathways has led to the development of treatment strategies consisting of a simultaneous blockade of both signalling pathways, as a reasonable approach to prevent the onset of mechanisms of resistance.This review was based...
Paper Details
Title
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
Published Date
Mar 16, 2021
Volume
51
Issue
7
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History